AstraZeneca PLC's new chief executive is working hard to convince investors and remaining staff that the troubled drug maker can turn its fortunes around. But it promises to be a long haul.
CEO Pascal Soriot’s strategy envisions the U.K.-based group emerging from the shadows of its patent cliff as a pure-play pharmaceutical innovator with a focus on three core therapeutic areas and an increased emphasis on specialty markets
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?